Pfizer halted the development of its daily weight loss pill, danuglipron, after one patient out of over 1,400 experienced a liver injury. The patient’s liver enzymes returned to normal quickly after discontinuing the drug. Despite this, the patient showed no liver-related symptoms or side effects. The decision followed a comprehensive review of clinical data and regulatory feedback. The trial involved rapidly increasing the dose of the pill. Although earlier studies met their goals and suggested potential efficacy and tolerability, the risk was deemed too high. The rate of elevated liver enzymes in danuglipron users aligns with other approved GLP-1 drugs. This setback is part of a series of challenges for Pfizer in the competitive GLP-1 market, projected to reach over $150 billion by the early 2030s, with oral GLP-1s potentially accounting for $50 billion. Despite this, Pfizer continues to explore other obesity treatments.
“Sudden And Unexpected”
@toobaffled
·
52m BREAKING: Pfizer abandons weight-loss pill after one liver injury.But vaccine injuries? No problem.Guess there’s no mandate to be skinny.
Gen Belisarius
@GenBelisarius
·
44m Pfizer has a plan: Fat Emergency Authorization for their new FatAssbnt162b2 mRNA vaccine. Yes it gives you cancer, myocarditis, auto immune disease, nerve damage and AIDS, but before you die you lose weight.Pfizer: We can do this!
Kellie
@Opinion8dKellie
·
3h Weird that Pfizer scraps daily weight loss pill after liver injury in one patient but vaccine injury was okay. I get it, no government mandate to lose weight.
Maarten
@MaartenDik
·
3h $PFE Pfizer scraps daily weight loss pill after liver injury in one patient.$VKTXhttps://cnbc.com/2025/04/14/pfizer-scraps-daily-weight-loss-pill-danuglipron.html?__source=iosappshare%7Ccom.apple.UIKit.activity.CopyToPasteboard…
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
